Sign up to save your podcasts
Or
Share S3E9 | Glucose-Lowering Drugs and COPD Exacerbations — Dual Benefits of SGLT2 and GLP-1 Therapy?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S3E9 | Glucose-Lowering Drugs and COPD Exacerbations — Dual Benefits of SGLT2 and GLP-1 Therapy?
New population-based study suggests SGLT2 inhibitors and GLP-1 receptor agonists may reduce COPD exacerbations in patients with type 2 diabetes.
In this episode of What's It Worth?, we examine a large real-world study assessing whether glucose-lowering medications influence the risk of COPD exacerbations in patients with type 2 diabetes and chronic obstructive pulmonary disease. We focus on SGLT2 inhibitors and GLP-1 receptor agonists and discuss whether potential pulmonary benefits should influence drug selection in patients with both conditions.
Guest: Ashley Wilke, PharmD — PGY2 Critical Care Pharmacy Resident at M Health Fairview East Bank Hospital.
Study at a Glance
- Design: Retrospective cohort study using nationwide claims and registry data
- Population: Adults with type 2 diabetes and COPD initiating glucose-lowering therapy
- Exposures: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors
- Primary outcome: COPD exacerbations requiring hospitalization or systemic steroids
- Key Finding: SGLT2 inhibitors and GLP-1 receptor agonists were associated with a lower risk of COPD exacerbations compared with DPP-4's
- KEY Caveats: Results are observational and this study cannot prove causality - only association.
- Tune in for our conclusions when we ask, "What's it Worth?"!
Key teaching points
1. SGLT2 inhibitors and GLP-1 RAs may reduce pulmonary inflammation and fluid overload, potentially contributing to fewer exacerbations.
2. In a patient with both COPD and type 2 diabetes, these agents may offer meaningful extra-glycemic benefits.
3. This evidence supports shared decision-making, not mandatory therapy selection
4. Pharmacists can identify dual-benefit opportunities and tailor therapy based on comorbidities, cardiovascular risk, and exacerbation history.
Citation: Patorno E, Feldman HA, Bykov K, et al. Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in type 2 diabetes. JAMA Intern Med. 2025;185(4):405-414. doi:10.1001/jamainternmed.2024.7811
🎧 If you find this episode helpful, follow and leave a quick rating—it helps other clinicians and learners find high-quality, evidence-based content.
🎧 Email me at [email protected] if you have an article suggestion for me to decode!
View all episodes
By Diana LangworthyNew population-based study suggests SGLT2 inhibitors and GLP-1 receptor agonists may reduce COPD exacerbations in patients with type 2 diabetes.
In this episode of What's It Worth?, we examine a large real-world study assessing whether glucose-lowering medications influence the risk of COPD exacerbations in patients with type 2 diabetes and chronic obstructive pulmonary disease. We focus on SGLT2 inhibitors and GLP-1 receptor agonists and discuss whether potential pulmonary benefits should influence drug selection in patients with both conditions.
Guest: Ashley Wilke, PharmD — PGY2 Critical Care Pharmacy Resident at M Health Fairview East Bank Hospital.
Study at a Glance
- Design: Retrospective cohort study using nationwide claims and registry data
- Population: Adults with type 2 diabetes and COPD initiating glucose-lowering therapy
- Exposures: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors
- Primary outcome: COPD exacerbations requiring hospitalization or systemic steroids
- Key Finding: SGLT2 inhibitors and GLP-1 receptor agonists were associated with a lower risk of COPD exacerbations compared with DPP-4's
- KEY Caveats: Results are observational and this study cannot prove causality - only association.
- Tune in for our conclusions when we ask, "What's it Worth?"!
Key teaching points
1. SGLT2 inhibitors and GLP-1 RAs may reduce pulmonary inflammation and fluid overload, potentially contributing to fewer exacerbations.
2. In a patient with both COPD and type 2 diabetes, these agents may offer meaningful extra-glycemic benefits.
3. This evidence supports shared decision-making, not mandatory therapy selection
4. Pharmacists can identify dual-benefit opportunities and tailor therapy based on comorbidities, cardiovascular risk, and exacerbation history.
Citation: Patorno E, Feldman HA, Bykov K, et al. Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in type 2 diabetes. JAMA Intern Med. 2025;185(4):405-414. doi:10.1001/jamainternmed.2024.7811
🎧 If you find this episode helpful, follow and leave a quick rating—it helps other clinicians and learners find high-quality, evidence-based content.
🎧 Email me at [email protected] if you have an article suggestion for me to decode!